Skip to main content

Table 2 Summary of RT-PCR amplification and sequencing success rate of clinical samples from telaprevir and VX-222 clinical trials

From: Development of a sensitive RT-PCR method for amplifying and sequencing near full-length HCV genotype 1 RNA from patient samples

HCV RNA (IU/mL)a Genotype/Subtypeb Numbers of clinical samples Success rate of RT-PCR amplification % (n/N) Success rate of sequencing % (n/N)
≥ 1000 1a 5400 97 (5238/5400) 99.6 (5218/5238)
  1b 2400 97 (2328/2400) 99.6 (2318/2328)
100–1000 1a 152 48 (73/152) 98.6 (73/73)
  1b 107 40 (43/107) 100.0 (43/43)
  1. aHCV RNA was assessed using the Roche TaqMan HCV RNA assay (Version 2.0).
  2. bGenotype and subtype was defined using 5'NC assay (Trugene) or Versant HCV genotype assay (LiPA) 2.0.